Infectious prions contain a self-propagating, misfolded conformer of the prion protein termed PrP Sc . A critical prediction of the protein-only hypothesis is that autocatalytic PrP Sc molecules should be infectious. However, some autocatalytic recombinant PrP Sc molecules have low or undetectable levels of specific infectivity in bioassays, and the essential determinants of recombinant prion infectivity remain obscure. To identify structural and functional features specifically associated with infectivity, we compared the properties of two autocatalytic recombinant PrP conformers derived from the same original template, which differ by >10
molecules should be infectious. However, some autocatalytic recombinant PrP Sc molecules have low or undetectable levels of specific infectivity in bioassays, and the essential determinants of recombinant prion infectivity remain obscure. To identify structural and functional features specifically associated with infectivity, we compared the properties of two autocatalytic recombinant PrP conformers derived from the same original template, which differ by >10
5
-fold in specific infectivity for wild-type mice. Structurally, hydrogen/deuterium exchange mass spectrometry (DXMS) studies revealed that solvent accessibility profiles of infectious and non-infectious autocatalytic recombinant PrP conformers are remarkably similar throughout their protease-resistant cores, except for two domains encompassing residues 91-115 and 144-163. Raman spectroscopy and immunoprecipitation studies confirm that these domains adopt distinct conformations within infectious versus non-infectious autocatalytic recombinant PrP conformers. Functionally, in vitro prion propagation experiments show that the non-infectious conformer is unable to seed mouse PrP C substrates containing a glycosylphosphatidylinositol (GPI) anchor, including native PrP C . Taken together, these results indicate that having a conformation that can be specifically adopted by post-translationally modified PrP C molecules is an essential determinant of biological infectivity for recombinant prions, and suggest that this ability is associated with discrete features of PrP Sc structure.
Introduction
The conformational conversion of the host-encoded prion protein (PrP) is a central pathogenic event in the prion diseases [1] . In healthy individuals, PrP adopts a fold that is rich in α-helix, termed PrP C , and is post-translationally modified by the incorporation of N-linked glycans and a C-terminal glycosylphosphatidylinositol (GPI) anchor. In individuals suffering from prion disease, PrP C is misfolded into a β-sheet rich conformation, termed PrP Sc , which is capable of acting as a template for the conformational conversion of additional PrP C molecules into PrP Sc . This self-propagating activity of PrP Sc is referred to as autocatalysis and is thought to underlie the infectious nature of the prion diseases. A critical prediction of the protein-only hypothesis is that autocatalytic PrP Sc molecules should be infectious.
A number of in vitro techniques for generating misfolded, autocatalytic PrP Sc conformers have been developed and refined, including the cell-free conversion assay [2] and the serial protein misfolding cyclic amplification (sPMCA) technique [3, 4] . With few exceptions, PrP Sc conformers derived from post-translationally modified, native PrP C substrates have been highly infectious when bioassayed in wild-type animals [4] [5] [6] [7] [8] . In contrast, various autocatalytic PrP Sc conformers derived from recombinant PrP substrates lacking post-translational modifications have displayed large variations in specific infectivity levels as determined by bioassay in wild-type animals [9] [10] [11] [12] [13] [14] [15] . The structural and functional basis of this striking variability in specific infectivity between different autocatalytic recombinant PrP Sc molecules remains unknown.
Recently, using only bacterially expressed recombinant PrP and a single endogenous phospholipid cofactor molecule, phosphatidylethanolamine (PE), as substrates, Deleault et al. successfully produced high titer (2.2 x 10 6 LD 50 U/μg PrP), chemically defined mouse prions in vitro [10] . Interestingly, it was observed that the prions produced from these minimal components always formed into a single infectious strain with unique, novel biological properties regardless of the seed originally used to template the in vitro reactions. Importantly, when this novel prion strain was subsequently propagated in the absence of PE cofactor, a new misfolded recombinant PrP conformer was produced, which could also self-propagate in sPMCA reactions, but which surprisingly failed to cause disease upon injection into wild-type mice [10] . This new autocatalytic conformer, which we refer to as protein-only PrP Sc , therefore had a >10 5 -fold lower level of specific infectivity as compared to the PrP Sc conformer produced in
We saw an opportunity to identify structural and functional properties associated with recombinant PrP Sc infectivity by directly comparing these two related PrP Sc conformers, which share the same origin and autocatalytic behavior, but differ strikingly in biological infectivity.
Results
Functional differences between cofactor and protein-only PrP Sc can be localized to their respective C-terminal, protease-resistant cores
Cofactor and protein-only PrP Sc are distinct misfolded recombinant PrP conformers that differ >10
5 -fold in their specific infectivity for wild-type mice [10] . While both of these conformers demonstrate autocatalytic activity when used to seed sPMCA reactions containing recombinant PrP substrate ( Fig 1A and [10 [16] ) (S1 Fig, top panel) and the extreme C-terminus (S1 Fig, bottom panel) . Based on these results, we focused our subsequent structural analyses on C-terminal residues beginning at glycine 89 (G89), the primary PK-cleavage site for PrP Sc 27-30 [17] .
Structural comparison of cofactor and protein-only PrP Sc by DXMS identifies conformational differences in restricted C-terminal domains
To compare the structures of cofactor PrP Sc and protein-only PrP Sc molecules, we performed hydrogen/deuterium exchange MS (DXMS) on these two conformers generated in parallel from the same OSU prion strain seed (Fig 2A) . The OSU prion strain was originally synthesized by Wang et al. using recombinant PrP, total liver RNA and 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphoglycerol (POPG) [15] , and it has previously been referred to as the OSU strain by Deleault et al. [10] . OSU-seeded cofactor and protein-only PrP Sc samples used for structural analysis in this study were generated with high conversion efficiency in sPMCA (S2 Fig) and then purified prior to DXMS analysis by a series of ultracentrifugation steps described in Materials and Methods. Co-sedimentation of significant quantities of non-specifically aggregated, protease-sensitive PrP was ruled out in the OSU-seeded cofactor PrP Sc DXMS sample due to its near complete conversion to PK-resistant PrP Sc (96% PK-resistant conversion efficiency, S2   Fig) . To assess the potential contribution of non-specifically aggregated, protease-sensitive PrP to the OSU-seeded protein-only PrP Sc sample analyzed by DXMS (77% PK-resistant conversion efficiency, S2 Fig) , we mock-seeded protein-only PMCA reactions and subjected the resulting material to the DXMS purification protocol (S3 Fig, top panel) . We did not detect any non-specifically aggregated PrP in these mock-seeded PMCA reactions (S3 Fig, top Sc experimental samples and used to construct ribbon diagrams in parts (A) and (B). Alternating shades of blue in part (C) are used to highlight neighboring peptides. Despite complete coverage of amino acids 89-230 by overlapping peptides, gaps exist in the ribbon diagrams shown in parts (A) and (B) for two reasons: 1. Deuterium incorporation cannot be quantified for the two N-terminal residues of a peptide as a result of rapid back exchange [19] , and 2. Proline residues lack amide hydrogen atoms and therefore do not contribute to deuterium incorporation measurements. study, specific regions of the PrP primary sequence are referred to either by explicit residue numbering, based on the mouse PrP sequence, or with reference to the location of known secondary structural elements in monomeric, α-helical recombinant PrP (α-PrP). For example, the domain corresponding to residues 178-216 could also be described as α 2 -α 3 because it encompasses the second and third α-helices in α-PrP.
The C-terminal cores of cofactor and protein-only PrP Sc are both substantially protected from solvent exchange (Fig 2A) as compared to α-PrP (S4 Fig) . This solvent protection is consistent with widespread conversion to β-sheet secondary structure and/or the formation of large solvent-excluding aggregates [20] . Convergence of biological strain properties is correlated with cofactor PrP Sc structural convergence
Deleault et al. [10] originally used three prion strains with distinct infectious phenotypes to seed the chemically-defined, recombinant PrP conversion system used to produce cofactor and protein-only PrP Sc molecules. Interestingly, the three input strains converged into a single strain with a novel biological phenotype upon propagation in sPMCA reactions containing only recombinant PrP substrate and a single cofactor. We used DXMS to examine the structures of the two additional cofactor PrP Sc samples generated by Deleault et al. in sPMCA reactions that were initially seeded with mouse prion strains distinct from the OSU strain (301C-and ME7-seeded cofactor PrP Sc ) ( Fig 2B) . The results revealed that the PK-resistant cores of all three cofactor PrP Sc molecules have nearly identical solvent accessibility profiles ( we therefore estimate that such non-specifically aggregated PrP accounts for no more than 2% of the sample analyzed by DXMS (ie. 8% of the unconverted, PK-sensitive material yields the estimate for non-specifically aggregated, PK-sensitive PrP, or~1.4% of the total input PrP, which is then divided by the sum of the PK-resistant and PK-sensitive insoluble PrP, or~83.4% of the total input PrP). We further sought to confirm a conformational difference between cofactor and proteinonly PrP Sc in the α 1 -β 2 domain using Raman spectroscopy (Fig 4) . Analysis of the Raman spectra acquired from these two conformers identified multiple Raman shifts that could be assigned to tyrosine residues, which are plentiful in the PrP C-terminus and specifically enriched in the α 1 -β 2 domain (6 of 11 total C-terminal tyrosines). By Raman spectroscopy, protein-only PrP Sc appears to contain more exposed tyrosine residues than cofactor PrP Sc as evidenced from the increased ring ν(C = C) intensity at~1620 cm -1 (Fig 4, left panel) , the 850 cm ratio being greater than 1 (Fig 4 , right panel) [22] , and the increased ring ν(CH) intensity at 3075 cm -1 (S8 Fig, left panel) [23, 24] , consistent with our DXMS results. In addition, and also Immunoprecipitation with conformation-specific mAb 15B3 distinguishes between cofactor and protein-only PrP Sc . Converted sPMCA products were purified by ultracentrifugation with nOG washes to remove unconverted α-PrP and excess lipid, and immunoprecipation was performed using 15B3-coated or uncoated rat anti-mouse IgM-conjugated magnetic beads, as indicated. The location of the discontinuous, 15B3 conformational epitope is shown in Fig 2A. Arrows indicate an M r of~23 kDa, the expected mobility of full-length recombinant PrP. By densitometry, the efficiency of 15B3 immunoprecipitation in this experiment is 79%, 71% and 74% for 301C-seeded, ME7-seeded, and OSU-seeded cofactor PrP Sc , respectively, and 15% for OSU-seeded protein-only PrP Sc . Amide II region, corresponding to ν(CN) and δ(CNH) Raman shifts (S8 Fig, right panel) , as well as an increased ν(CN) intensity at~3300 cm -1 (S8 Fig, left panel) . These exposed CNH groups likely originate from the 4 exposed arginine (R) and single exposed glutamine (Q), asparagine (N) and tryptophan (W) residues in the α 1 -β 2 domain, or from CNH-containing side chains in the N-terminal portion of the PK-resistant PrP Sc core (residues~91-115).
Cofactor and protein-only PrP Sc differ functionally in the ability to convert GPI-anchored substrates Our DXMS data suggests that structural differences between cofactor and protein-only PrP Sc are limited to specific domains (Fig 2A) and that these structural differences affect the ability of recombinant PrP Sc to convert native PrP C ( Fig 1B) . As conversion substrates, α-PrP and native PrP C share the same primary sequence, but PrP C also contains bulky N-linked glycans and a GPI anchor as post-translational modifications. Therefore, we hypothesized that limited conformational differences might dramatically alter a recombinant conformer's infectious activity by impinging on spatial regions that would be occupied by N-linked glycans or a GPI anchor should PrP C adopt the same conformation. To test this hypothesis, we partially purified native Comparison of Infectious & Non-Infectious Autocatalytic PrP Conformers digestion products of slightly higher apparent molecular weight than the respective input seeds (Fig 5 and S9 Fig, left and middle sample groups, round 1 vs 0). In the case of protein-only PrP Sc , this higher molecular weight product is diluted out in proportion to the initial seed ( Fig 5 and S9 Fig, left By comparing the structures of these two conformers using DXMS, we find that cofactor and protein-only PrP Sc molecules have remarkably similar solvent accessibility profiles within the PK-resistant PrP Sc core (Fig 2A) . Indeed, they are virtually indistinguishable by this measure in the domains that correspond roughly to α 2 -α 3 in α-helical PrP (~residues 165-230), and to the stretch of residues between the hydrophobic domain and the start of α 1 (~118-143) (Fig 2A) , both displaying significant protection from solvent exchange, consistent with widespread conversion to β-sheet secondary structure. The degree of solvent protection, especially N-terminal to β 2 , distinguishes cofactor and protein-only PrP Sc from synthetic PrP amyloids [27] [28] [29] [30] [31] , and is most consistent with previous DXMS studies using brain-derived and recombinant prions [27, 32, 33] . Like these recent DXMS studies, the data from the present study are consistent only with those models of PrP Sc structure that involve a complete refolding of the PrP C C-terminal α-helices to β-sheet-for example, the parallel in-register β-sheet architectures proposed by Cobb et al. [34] and more recently by Groveman et al. [35] . Interestingly, the modest increase in solvent accessibility seen at residues 187-196 in all four PrP Sc conformers studied here (Fig 2) corresponds well with the proposed loop of the native disulfide hairpin predicted by both of these models. In addition to broad similarities between cofactor and protein-only PrP Sc in solvent accessibility, we have identified two specific domains in which the cofactor and protein-only PrP Sc conformers can be conformationally distinguished: most clearly within the domain that corresponds to α 1 through the C-terminus of β 2 in PrP C (~residues 144-163), but also within a domain at the N-terminus of the PK-reistant core, comprising residues~91-115 (Fig 2A) . In both of these domains, protein-only PrP Sc appears to be more exposed to solvent exchange than cofactor PrP Sc . Given the role PE cofactor molecules play in the formation of cofactor, but not protein-only, PrP Sc [10] , it is likely that the relatively solvent-protected structural features selectively associated with cofactor PrP Sc are cofactor-induced. Moreover, the fact that the PKresistant cores of all three cofactor PrP Sc samples, derived from distinct prion strains but propagated in the same chemically-defined system, are highly similar (Fig 2A and 2B) suggests that the convergence of biological strain properties observed by Deleault et al. [10] is associated with a convergence of PrP Sc structure.
The α 1 -β 2 domain, which appears to adopt different conformational states in cofactor and protein-only PrP Sc (Figs 2-4) , has previously been identified as a region of PrP that has important implications for PrP misfolding. For example, several PrP Sc -selective conformational antibodies are known to have epitopes that reside within this domain [18, 36] , and small deletions towards the C-terminus of this domain produce PrP molecules that do not readily form PrP Sc and, in fact, function as dominant-negative inhibitors of PrP Sc replication in full-length PrP substrates [37] . Moreover, in the complete absence of the α 1 -β 2 domain, a redacted 'miniprion' is capable misfolding to form PrP Sc , but does not cause disease when inoculated into animals expressing full-length PrP [38, 39] . Interestingly, the α 1 -β 2 domain lies adjacent the β 2 -α 2 loop, a region of PrP known to play an important role in prion formation and interspecies prion transmission [40] [41] [42] [43] .
Less is known about the second domain (amino acids~91-115) in which cofactor and protein-only PrP Sc appear to adopt different conformational states (Fig 2 and S5 Fig) . This domain includes the so-called 'fifth site' for Cu 2+ binding [44] [45] [46] .
It is important to acknowledge that any comparisons drawn between DXMS results in the present study and the activities of cofactor and protein-only PrP Sc are correlations only, and that it is possible the structural features underlying PrP Sc -associated activities such as autocatalysis and infectivity may be subtle and/or beyond the resolution of the DXMS approach. Similarly, it should be acknowledged that DXMS provides a measure of the average deuterium incorporation at a given amide proton position over a population ple. In addition, it should be made clear that when interpreting ribbon diagrams, as in Fig 2, similar solvent accessibility profiles do not guarantee similar tertiary and/or quaternary structures, although by using a set of matched peptides with dense, overlapping coverage of the region of interest (Fig 2C) to compare the solvent accessibility of the cofactor and protein-only PrP Sc conformers, we have increased confidence in such an interpretation of the data. Finally, we do not claim that a relatively solvent inaccessible conformation of either of the two structurally divergent domains identified in the present study is required for PrP Sc infectivity generally.
The data presented here are specific to the situation in which seed and substrate are both of the mouse PrP sequence, and it is possible that different PrP sequences may have different infectivity-associated conformational spaces. Consistent with a sequence-specific interpretation of our results, it has previously been shown that native mouse prions also appear to have a relatively solvent-protected structure in the α 1 -β 2 domain [27] , while a recent study showed that this same domain is relatively solvent exposed in native human prions [33] . [49] .
To integrate the results of our structural and functional comparison of cofactor and protein-only PrP Sc , we propose a model to account for the striking variation in specific infectivity observed for recombinant PrP Sc conformers [9] [10] [11] [12] [13] [14] [15] (Fig 6) . In this model, the PrP polypeptide backbone, represented by recombinant PrP, is capable of adopting a wide variety of autocatalytic conformations. However, post-translationally modified, native PrP C can only adopt a subset of these conformations, and this subset represents the infectious recombinant PrP Sc conformers. From previous studies of PrP and other proteins, there is evidence to suggest that post-translational modifications can alter or restrict protein folding pathways. Indeed, Nlinked glycans are known broadly to have chaperone-like effects and to contribute to protein stability [51] . In the case of PrP, it has been observed that the presence of glycans can alter the rate of amyloid fibril formation [52, 53] , and that by restricting available PrP glycoforms it is possible to control prion strain susceptibility [54] . Whether GPI anchors play a role in protein folding or misfolding is less clear. The loss of the GPI anchor of PrP (which is concomitant with a significant reduction in PrP C glycosylation in vivo [55] ) appears to have only a modest effect on PrP Sc structure [56] , but substantially alters the biochemical properties of PrP Sc and promotes the formation of fibrillar aggregates [57, 58] and interferes with PrP Sc replication in vitro [49] . Interestingly, the co-expresssion of anchorless and wild-type PrP C molecules in vivo appears to enhance host susceptibility to recombinant PrP amyloid fibrils [59] , while the experimental addition of a GPI anchor to the amyloidogenic yeast protein, Sup35p, prevents the formation of fibrillar structures, leading instead to the formation of PrP Sc -like, non-fibrillar aggregates [60] . While the data from the present study specifically point to a role for the GPI anchor of native mouse PrP C in restricting the range of recombinant PrP Sc conformers that possess infectious activity, we cannot exclude the possibility that N-linked glycans also influence the infectivity-associated recombinant PrP Sc conformational space. In fact, we speculate that the boundaries of this subset of the conformational space are likely to be highly contextdependent, determined by a complex interplay between the polypeptide sequence of a given PrP C substrate molecule and all of its associated post-translational modifications. 
Comparison of Infectious & Non-Infectious Autocatalytic PrP Conformers
In conclusion, we report for the first time a structural and functional comparison between two autocatalytic recombinant PrP Sc conformers that share the same origin and biochemical behavior, but differ >10
5
-fold in infectious titer for wild-type mice. Based on our findings, we suggest that those autocatalytic recombinant PrP Sc conformers which are also highly infectious contain specific structural features in a limited number of PrP domains, and that these features may be required in order to accommodate specific substrate post-translational modifications during native PrP C misfolding in vivo.
Materials and Methods
Preparation of cofactor and protein-only PrP Sc by sPMCA
Cofactor and protein-only PrP Sc [10] were generated by sPMCA as described [10] . Briefly, 100- 
Detection of cofactor and protein-only PrP Sc
Formation of cofactor and protein-only PrP Sc was monitored by digestion of PMCA samples with proteinase K (PK) and Western blotting. Samples were treated with 25 μg/ ml PK (Roche) for 30 min at 37°C, and digestion reactions quenched by the addition of SDS-PAGE loading buffer and heating to 95°C for 10 min. SDS-PAGE and Western blotting were performed as described previously [10] using mAb 27/33, unless otherwise specified.
Purification and epitope mapping of cofactor and protein-only PrP Sc PKresistant cores All centrifugation was done at 4°C. Cofactor and protein-only PrP Sc PMCA products were treated or mock-treated with PK as described above and the reaction quenched by the addition of PMSF to 5 mM final concentration. To remove PK, excess lipids, and any soluble recombinant PrP digestion products, digested PrP Sc was washed twice with nOG wash buffer (1% noctyl-beta-D-glucopyranoside (nOG), 150 mM NaCl, 8.3 mM Tris pH 7.2) by centrifugation at 100,000 rcf for 1 h, with resuspension by sonication (60-s pulse, 70 amplitude) followed by brief vortexing. After the second wash, samples were pelleted by centrifugation at 100,000 rcf for 1 hr and resuspended in conversion buffer by sonication and vortexing to a recombinant PrP concentration of 6 μg/ml for use in epitope mapping and sPMCA experiments. Epitope mapping of the cofactor and protein-only PrP Sc PK-resistant cores was performed using mAbs 6D11 [61] and R2 [62] . Aliquots of identical purified samples were run on SDS-PAGE, transferred to PVDF membrane, and processed independently by Western blotting using trays and containers that had never been in contact with anti-PrP antibodies.
sPMCA with native PrP C and deglycosylated PrP C substrates
For normal brain homogenate sPMCA, brain homogenates were prepared at 10% (w/v) in conversion buffer (PBS containing 1% (v/v) Triton X-100 and cOmplete protease inhibitor cocktail (Roche)) from healthy C57BL/6 mice, as described by Castilla et al. [5] . Homogenates were clarified by brief sonication (F60 Sonic Dismembrator (Fisher Scientific), three 5-s pulses at 1.8 amplitude), followed by centrifugation at 500 rcf for 15 min. Clarified substrates were then seeded with 1/10 th volume of purified PrP Sc samples, and sPMCA carried out as described above, with 20-s sonication pulses every 30 min. For deglycosylated PrP C sPMCA, diglycosylated native PrP C was first purified from normal mouse brain and then fully deglycosylated by treatment with PNGase F (New England Biolabs) as described [63] . Deglycosylated PrP C sPMCA reactions [63] were seeded with 5% (v/v) of recombinant or brain-derived PrP Sc and sonicated as described above for normal brain homogenate sPMCA.
Deuterium exchange and quenching of cofactor and protein-only PrP
Sc
All centrifugation was done at 4°C. Samples were prepared for deuterium exchange as described previously [32] with the following modifications. For each PrP Sc species, converted PMCA cocktail was washed twice with nOG wash buffer (1% n-octyl-beta-D-glucopyranoside (Anatrace), 150 mM NaCl, 8.3 mM Tris pH 7.2) by centrifugation at 100,000 rcf for 1 h, with resuspension by 60 s of sonication at 70 amplitude followed by brief vortexing. After the second wash, samples were pelleted by centrifugation at 100,000 rcf for 1 hr and resuspended in a volume of mock labeling buffer (150 mM NaCl, Deuterium exchange and quenching of α-helical recombinant PrP and preparation of equilibrium-deuterated controls
Deuterium exchange and quenching of normally folded, α-helical recombinant PrP (α-PrP) was performed as described above for cofactor and protein-only PrP Sc , with the following modifications. Recombinant PrP was resuspended to 1.0 mg/ml in water and an equal volume of 2x labeling buffer (D 2 O containing 300 mM NaCl, 16.6 mM Tris, pH Ã 7.2) was added to initiate deuterium exchange. Thirty minutes prior to quenching, an aliquot of the labeling reaction was placed at 4°C to replicate the temperature change experienced by PrP Sc samples during centrifugation. Deuterium-labeled α-PrP was then quenched on ice for 2 min by the addition of 1.25 volumes of ice-cold quench buffer containing 700 mM TCEP. To the quenched samples was added 1.30 volumes of ice-cold acid diluent prior to aliquoting into autosampler microvials and freezing on dry ice, as described above.
Equilibrium-deuterated samples were prepared by resuspension of recombinant PrP in 2.5 or 6.0 M guanidine hydrochloride solution containing a 1:1 molar ratio of protons:deuterons by mixing appropriate quantities of H 2 O, D 2 O, guanidine HCl and guanidine (D 6 ) DCl (Cambridge Isotope Laboratories, Andover, MA). Deuterium exchange was allowed to proceed for 72 hours at room temperature (22°C) prior to quenching as described above for α-PrP.
Quantification of co-sedimentation of protease-sensitive, insoluble PrP in DXMS PrP Sc samples
To estimate the fraction of non-specifically aggregated PrP that could potentially co-sediment during the purification of PrP Sc samples for DXMS, mock-seeded PMCA reactions were performed using PMCA cocktail supplemented with brain-derived cofactor or water. After 24 h of PMCA, the mock-seeded PMCA reactions were purified by ultracentrifugation as described above for DXMS samples and the fraction of the input PrP that was recovered as non-specifically aggregated, insoluble PrP was quantified by Western blot.
Analysis of deuterium incorporation
Measurement of deuterium incorporation by LC-MS was performed as described previously [32] , with the following modifications. Samples were loaded onto the in-line immobilized fungal protease XIII column at a rate of 60 μl/min, allowed to digest for 3 min, and then pushed onto the in-line immobilized pepsin column at a rate of 20 μl/min. Peptides were collected during pepsin digestion on a C18 trap column (Michrom MAGIC C18AQ, 0.2x2) preceding the C18 resolving column (Michrom MAGIC C18AQ, 0.2x50). All measurements were made on an Orbitrap Elite mass spectrometer (Thermo Fisher Scientific), and data was analyzed as described previously [32] .
Immunoprecipitation of cofactor and protein-only PrP Sc with mAb 15B3
Rat anti-mouse IgM-conjugated Dynabeads (Life Technologies) were washed according to the manufacturer's protocol and coated with mAb 15B3 (Prionics) at 5 μg per 10 μl beads with gentle mixing at room temperature for 2 h. Coated beads were washed three times to remove unbound antibody and stored at 4°C for no more than one week prior to use. Converted cofactor or protein-only PrP Sc PMCA cocktail was washed twice with nOG wash buffer as described above for the preparation of samples for DXMS. After the second wash, samples were collected by centrifugation at 100,000 rcf for 1 hr at 4°C and the pellet was gently washed with Prionics homogenization buffer (Prionics). Samples were then centrifuged at 100,000 rcf for 10 min at 4°C and the supernatant discarded. The pellet was resuspended in Prionics homogenization buffer by sonication (30-s pulse, 70 amplitude) and vortexing to a final concentration of 60 ng/μl PrP. For each PrP Sc sample,~250 ng PrP was added to 0.5 ml Prionics IP buffer (Prionics) and to this was added 10 μl of beads that were either coated with 15B3 or uncoated. Samples were allowed to interact with the beads at room temperature for 4 h with gentle mixing, followed by two washes with Prionics IP buffer and resuspension of the beads in 2x SDS-PAGE loading buffer. Samples were incubated at 95°C for 10 min, briefly centrifuged to concentrate the beads and the supernatant was collected for analysis by Western blot.
Raman spectroscopy of cofactor and protein-only PrP Sc
Cofactor and protein-only PrP Sc were generated by sPMCA supplemented with synthetic plasmalogen PE (Avanti Polar Lipids) as the sole cofactor, as described previously [64] . Converted PMCA cocktail was digested with PK as described above and quenched by the addition of PMSF (Sigma Aldrich) to 2 mM final concentration. Digested samples were washed twice with nOG wash buffer, as described above, and then twice with water to remove residual buffer components and detergent. Samples were then resuspended in water to a concentration of 140 ng/μl PrP by vortexing and a 15-s sonication pulse. 10 μl of the resulting sample was spotted onto a glass slide and allowed to dry under a stream of nitrogen. Once dry, another 10 μl was spotted on top of the first and again allowed to dry under nitrogen. Spotted samples were scanned using a WITec CRM200 Raman confocal light microscope, equipped with a 100x lens and a 514 nm argon laser with 45 mW output. An f/4, 300 mm imaging spectrograph was employed with 2 exit ports and a 600 lines/mm grating, with a Peltier-cooled CCD, 1340 x 100 pixel format, and a 16-bit camera controller. The fiber optic connecting the microscope with the spectrograph was 50 μm in diameter. Spectra were acquired using an integration time of 8 s, with two hardware and two software accumulations per shot and a spectral resolution of 4 cm -1 . Presented spectra are averages of 20-30 shots. In each figure, the baseline was adjusted to zero and data points were joined with a smoothed line in Microsoft Excel. Although spectral normalization was not possible, data were collected with the same instrument at the same time from highly concentrated films of protein, and it can be expected that intensity differences between samples originate in structural differences between conformers.
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Supporting Information To estimate the quantity of non-specifically aggregated PrP that could potentially co-sediment during the purification of PrP Sc samples for DXMS labeling, mockseeded PMCA reactions were performed using PMCA cocktail supplemented with brain-derived cofactor or water. After 24 h of PMCA, the mock-seeded PMCA reactions were purified by ultracentrifugation as described, with proportional samples of the supernatant/pellet taken during each of the three 100,000 rcf purification spins and analyzed by Western blot (labeled S 1 , P 1 , S 2 , P 2 , S 3 , P 3 ). Sample S 0 denotes mock-seeded PMCA material after 24 h of intermittent sonication and prior to ultracentrifugation. PK digestion was performed on the input and final pellet samples (S 0 and P 3 , respectively) to determine protease resistance. Densitometry reveals that~8% of the mock-seeded sample becomes non-specifically aggregated in PMCA reactions containing brain-derived cofactor (bottom panel, sample P 3 vs S 0 ). No non-specifically aggregated PrP was detected in protein-only mock-seeded PMCA reactions (top panel, sample P 3 vs S 0 ). (TIF) S4 Fig. Regional solvent accessibility of α-PrP. 104 peptides, including different peptide charge states, were recovered in two technical replicates and the average deuterium incorporation of overlapping peptides was used to determine regional solvent accessibility, as described. Regions of NMR-assigned α-helix and β-strand structure are indicated by green spirals and black arrows, respectively [3] . The data presented spanning Raman shifts of 1500-1800 cm -1 is the same as that presented 
